Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Encainide: a new antiarrhythmic agent.

A E Wehmeyer, R L Thomas

    Drug Intelligence & Clinical Pharmacy
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Encainide, a type Ic antiarrhythmic, effectively treats ventricular and supraventricular arrhythmias, including Wolff-Parkinson-White syndrome. It offers a safe option for refractory cases with minimal side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    IDF diabetes Atlas: A worldwide review of studies utilizing retinal photography to screen for diabetic retinopathy from 2017 to 2024 inclusive.

    Diabetes research and clinical practice·2025
    Same author

    Trends in certifications of overall vision impairment and that due to diabetic retinopathy/maculopathy in England and Wales, 2009/2010 to 2019/2020: a retrospective database analysis.

    BMJ open·2025
    Same author

    IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018.

    Diabetes research and clinical practice·2019
    Same author

    Properties and Function of the Flexor Hallucis Capsularis Interphalangeus Tendon.

    Clinical anatomy (New York, N.Y.)·2019
    Same author

    Acute shoulder injuries: A clinical review of diagnosis and management in the deployed Naval environment.

    Journal of the Royal Naval Medical Service·2018
    Same author

    Cancer survivors' concealment or disclosure of diagnosis: Implications for return to work.

    Work (Reading, Mass.)·2015
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    Area of Science:

    • Pharmacology
    • Cardiology

    Background:

    • Encainide is a type Ic antiarrhythmic agent.
    • Its bioavailability is affected by first-pass metabolism, leading to extensive and poor metabolizer phenotypes.
    • Active metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, contribute to its efficacy.

    Purpose of the Study:

    • To evaluate the efficacy and safety of encainide in treating cardiac arrhythmias.
    • To identify its role in managing refractory ventricular and supraventricular arrhythmias.

    Main Methods:

    • Clinical trials were conducted to assess encainide's effectiveness.
    • Patient responses and adverse effects were monitored.

    Main Results:

    • Encainide demonstrated high efficacy in suppressing premature ventricular contractions and ventricular tachyarrhythmias.

    Related Experiment Videos

  • It proved effective for refractory ventricular arrhythmias and supraventricular arrhythmias, particularly Wolff-Parkinson-White syndrome with short refractory periods.
  • Common side effects included dizziness, visual disturbances, nausea, and headache.

    • Conclusions:

    • Encainide is a safe and effective antiarrhythmic agent with negligible hemodynamic effects.
    • It is a valuable therapeutic option for various ventricular and supraventricular arrhythmias, especially those unresponsive to other treatments.